Cell Therapy News Volume 7.03 | Jan 30 2006

    0
    23
    Volume 7.03, January 30, 2006
         In this issue: Science | Policy | Business | NIH | CBER | Regulatory
    Cell Therapy News on Facebook  Cell Therapy News on Twitter

    Top Stories

    Discoveries May Advance Stem Cell Therapy for Parkinson’s, Cancer Patients: Researchers at the Karolinska Institutet in Sweden discovered a “master determinant” that turns embryonic stem cells into bona fide dopamine neurons, brain cells that degenerate in those with Parkinson’s disease.
    Article

    Science

    Cell Therapy Offers New Hope
    The findings by researchers may lead to improved stem cell therapies for patients with compromised immune systems due to intensive cancer therapy or autoimmune disease.
    Article

    Universities Team Up to Pursue Stem Cell Research
    Just weeks after the discovery that South Korean scientist Hwang Woo-suk forged what would have been influential stem cell research data, Yale announced it will join forces with Wesleyan University and the University of Connecticut in an attempt to push the science of stem cells forward and restore any lost credibility to the field.
    Article

    Researchers Identify Major Source Of Muscle Repair Cells
    In a surprising discovery with implications for treating muscular dystrophy, researchers at the University of Utah School of Medicine and other institutions have identified a major source of origin for two groups of adult cells that regulate muscle repair.
    Article

    Developing Non-invasive Technique To Detect Transplant Rejection At Cellular Level
    Carnegie Mellon University scientist Chien Ho and his colleagues have developed a promising tool that uses magnetic resonance imaging (MRI) to track immune cells as they infiltrate a transplanted heart in the early stages of organ rejection.
    Article

    South Korean Cloning Expert’s Stem Cells Do Not Exist
    Prosecutors confirmed that cloning expert Hwang Woo-Suk had fabricated key research, raising the likelihood that criminal charges could be filed against the disgraced South Korea scientist.
    Article

    Bulgaria Breaks New Ground for Cancer Vaccine Testing
    Bulgaria will become the first European country to hold clinical studies of an anti-cancer vaccine by Dr. Kenichiro Hasumi, a physician specialized in cancer immunotherapy and terminal care.
    Article

    Allergy Cell Holds Treatment Hope
    Scientists say they have found how a cell involved in allergy is made, which may help with finding new treatments.
    Article

    A Little Telomerase Just Isn’t Enough, Geneticists Find
    With seed money from the Johns Hopkins Institute for Cell Engineering, a Johns Hopkins geneticist and her team have discovered a critical link between the health of stem cells and the length of the chromosome ends within them.
    Article

    Procedure Allows Women to Freeze Eggs to Preserve Future Fertility
    Researchers at the Yale Fertility Center are now offering a cutting edge reproductive procedure called oocyte cryopreservation that allows women to freeze their eggs and use them at a later time to conceive a child.
    Article

    Carbon Nanotubes that Detect Disease-causing Mutations Developed by Pittsburgh Researcher
    University of Pittsburgh researcher Alexander Star and colleagues at California-based company Nanomix, Inc., have developed devices made of carbon nanotubes that can find mutations in genes causing hereditary diseases, they report in the Jan. 16 issue of the journal Proceedings of the National Academy of Science.
    Article

    Clinical Research Organizations Expand Speed and Capacity of Pharmaceuticals’ Product Development Pipeline, Tufts Study Finds
    The proportion of resources involved in pharmaceutical product development has shifted from drug and biotechnology companies to contract Clinical Research Organizations (CROs) over the last five years, according to a survey by the Tufts Center for the Study of Drug Development.
    Article

    ABSTRACT, REVIEWS, & SPECIAL REPORTS

    Identification of Intrinsic Determinants of Midbrain Dopamine Neurons
    These data establish that Lmx1a and Msx1 are critical intrinsic dopamine-neuron determinants in vivo and suggest that they may be essential tools in cell replacement strategies in Parkinson’s disease.
    Abstract

    Signals from the Sympathetic Nervous System Regulate Hematopoietic Stem Cell Egress from Bone Marrow
    These results indicate that the sympathetic nervous system regulates the attraction of stem cells to their niche.
    Abstract

    Policy

    Senator Schumer Introducing Legislation To Regulate Tissue Transplants, USA
    Sen. Charles Schumer (D-N.Y.) on Monday announced that he is proposing legislation that would regulate tissue transplants and donations.
    Article

    Watchdog Suggests Stem Cell Policies for California
    A taxpayer watchdog group is expected to release a report today (Jan. 23) outlining how leaders of the state’s $3 billion stem cell initiative could develop policies to make stem-cell-based therapies affordable and accessible to Californians.
    Article

    Thailand Plans Systematic Stem Cell Research
    Thailand sets up a national committee to build underlying framework for the kingdom’s systematic study of factors concerning research and development of stem cell applications to prevent exploitation from foreign firms.
    Article

    New Dehli Government to Act Against Clinic Using Stem Cell Therapy
    The Government has ordered an inquiry into the activities of a fertility clinic conducting embryonic stem cell therapy and warned of stringent action against those found violating the rules and guilty of playing with the health of unsuspecting patients, Health Minister Anbumani Ramadoss said.
    Article

    Business

    BrainStorm Files Patent Application for Stem Cell Procedure with Potential for Multiple Sclerosis Therapy
    BrainStorm Cell Therapeutics (OTCBB:BCLI), the developer of NurOwn(TM) bone marrow derived stem cell therapeutic products for the treatment of neurodegenerative diseases, announced today that a patent application has been filed with the US Patent and Trademark Office for a new procedure to derive oligodendrocyte-like cells.
    Article

    Cytori Therapeutics Receives CE Mark for the Celutionâ„¢ Stem Cell System; Achieves Condition for $11.0 Million Milestone Payment from Olympus Collaboration
    This approval is the first CE Mark given for a device that can process adult stem cells from adipose (fat) tissue.
    Article

    Geron Announces Improved Production Method for Human Embryonic Stem Cell-Derived Islet Cells
    Geron Corporation (Nasdaq:GERN) announced today the presentation of a new production protocol to differentiate islet cells from human embryonic stem cells (hESCs) for the treatment of diabetes.
    Article

    Amgen and Genentech Sign License Agreements For Antibody Patents
    Amgen (NASDAQ:AMGN) and Genentech Inc. (NYSE:DNA) today announced that they have entered into license agreements granting licenses to each other under multiple patents relating to the manufacture and use of antibodies and related technology.
    Article

    Amgen to Make Significant Investment in Manufacturing, R&D and Commercial Operations Expansion
    Amgen (Nasdaq: AMGN), the world’s largest biotechnology company, today announced that it anticipates significant investment in additional manufacturing and R&D operations in the United States and Europe and expansion of its commercial operations into new markets.
    Article

    Becton Dickinson Studies Stem Cell Market
    U.S. medical products company Becton Dickinson and Co. (BDX.N: Quote, Profile, Research) has started to explore the commercial potential of stem cells as a treatment for diabetes, its chief executive said on Wednesday.
    Article

    ReNeuron Receives Notice of Allowance from US Patent Office for Neural Stem Cell Transplantation Patent Application
    ReNeuron Group plc (LSE: RENE.L) today announced that it has received a Notice of Allowance from the US Patent and Trademark Office concerning a key patent application for methods of transplantation of neural stem cells.
    Article

    Medistem Reports Novel Method of Immunomodulation Through Genetic Reprogramming of Immune Cells Medistem Laboratories, Inc. (OTCBB:MDSM), committed to the ethical development of next-generation medical therapies from non-controversial adult stem cell sources, announced today the successful development of a novel method of immune response modification utilizing a genetic reprogramming technology involving RNA interference.
    Article

    Weizmann Institute Scientists Suggest that Immune Cells Help to Maintain Cognition and Brain Cell Renewal
    A team of scientists at the Weizmann Institute of Science, led by Prof. Michal Schwartz of the Neurobiology Department, has come up with new findings that may have implications in delaying and slowing down deterioration of memory and learning ability in old age.
    Article

    Targeted Genetics Corporation (TGEN) Strengthens Intellectual Property For AAV Vector Manufacturing Purification Processes
    Targeted Genetics Corporation (Nasdaq:TGEN) today announced the issuance of an additional patent related to its adeno-associated virus (AAV) vector manufacturing processes. U.S. patent #6,989,264 is titled, “Methods for generating high titer helper-free preparation of released recombinant AAV vectors.”
    Article

    Shareholders of Inex Pharmaceuticals Approve Spin Out of Targeted Immunotherapy Assets
    Inex Pharmaceuticals Corporation (“INEX”;TSX: IEX) announced that at its Special Meeting of Shareholders held today, shareholders of INEX approved the Plan of Arrangement to complete the spin-out of INEX’s Targeted Immunotherapy assets into a new company, Tekmira Pharmaceuticals Corporation (“Tekmira”) with 98.3% of shares cast voting in favour of the spin-out.
    Article

    FDA Blasts Boston Scientific Over cGMP Violations
    The FDA is putting Boston Scientific on notice that the company’s quality management practices are insufficient, with “serious regulatory problems” being found at numerous facilities.
    Article

    MicroIslet Appoints Dr. James R. Gavin III Interim President and CEO
    MicroIslet, Inc. (Amex: MII) today announced that it has appointed James R. Gavin III, M.D., Ph.D., as its interim President and CEO, effective January 20, 2006. Dr. Gavin has been a member of MicroIslet’s Board of Directors since March 2001.
    Article

    NIH


    NATIONAL INSTITUTES OF HEALTH

    Application of Emerging Technologies for Cancer Research (SBIR[R43/R44]) (RFA-CA-07-008)
    Link

    Application of Emerging Technologies for Cancer Research (STTR[R41/R42])(RFA-CA-07-009)
    Link

    CBER

    All new CBER information can be reached from the What’s New page at What’s New Page

    Cellular, Tissue and Gene Therapies Advisory Committee Meeting
    Link

    Vaccines and Related Biological Products Advisory Committee
    Link

    Ninth Annual FDA and the Changing Paradigm for Blood Regulation Workshop – Slide Presentation
    Link

    Regulatory

    Food & Drug Administration (United States of America)

    Cellular, Tissue and Gene Therapies Advisory Committee: Nature and Basis Statements of Conflict(s) of Interest for Voting Members of FDA Advisory Committee Members
    Link

    Oncologic Drugs Advisory Committee; Amendment of Notice
    Link

    ISCT

    ISCT2006. May 4-7. Berlin.
    Click here for the Call for Abstracts and preliminary program or registration information.

    AABB-ISCT Cellular Therapy Audioconference Series
    Link

    Profiled Journal

    Editor-in-Chief:
    Robert Weinstein, MD
    Chief, Hematology and Transfusion Medicine, Caritas St. Elizabeth’s Medical Center, Tufts University School of Medicine, Boston, MA

    The Journal of Clinical Apheresis provides the world’s premier source of current information in the field of apheresis. The Journal presents work in all aspects of basic and clinical research, practical applications, emerging technologies and regulation in apheresis and related fields including hematology, nephrology, neurology, rheumatology, transplantation, cellular therapies, blood banking, transfusion medicine, and others.

    A subscription to the journal is a key benefit of ASFA membership, which ranges from $120-145 annually. To become a member please contact:

    ASFA Head Office
    570 West 7th Ave, Suite 402
    Vancouver, BC V5Z IB3, Canada
    T 604-484-2851
    F 604-874-4378
    E asfa@apheresis.org
    www.apheresis.org

    Please visit the website for all you need to know about publishing in or subscribing to the Journal of Clinical Apheresis:
    http://www.interscience.wiley.com/journal/jca